+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of nipocalimab compared to a placebo in adults with chronic inflammatory demyelinating polyneuropathy CIDP who initially respond to nipocalimab treatment. The study focuses on delaying relapse in this population and involves multiple phases and stages to assess the treatments impact. This trial is sponsored by Janssen Research & Development, LLC and includes adults diagnosed with CIDP according to specific criteria. Participants first enter Stage A, where they receive an initial loading dose of nipocalimab by intravenous infusion on Day 1, followed by doses every two weeks from Week 2 to Week 12. Those who show clinical improvement proceed to Stage B, a double-blind phase where they are randomly assigned to receive either nipocalimab or placebo infusions every two weeks for up to 52 weeks. Following Stage B, participants may join an open-label extension phase to continue receiving nipocalimab every two weeks until two years after the drugs marketing authorization in their country or until it becomes commercially available. Throughout the study, participants undergo regular assessments including evaluations of disability, muscle strength, grip strength, and disease activity scores. Researchers monitor for relapses, adverse events, and changes in laboratory and clinical parameters. The primary outcome measures include the time to first relapse during Stage B, with additional secondary outcomes assessing clinical improvements, safety, and immunologic responses. Total participation may last several years depending on extension phase involvement.

Age: 18Years +All GendersPhase 2Phase 3
120 locations